Experimental 'gene silencing' therapy reduces lipoprotein(a), an important risk factor of heart disease, by up to 98%

Findings from a phase 1 trial show that an experimental 'gene silencing' therapy reduced blood levels of lipoprotein(a), a key driver of heart disease risk, by up to 98%.